
Bio-Techne (TECH) Stock Forecast & Price Target
Bio-Techne (TECH) Analyst Ratings
Bulls say
Bio-Techne's financial outlook reflects a stable revenue trajectory, with new estimates projecting revenues of $315.0 million, marking a 3% increase compared to the previous quarter. Additionally, the company's adjusted earnings are expected to rise to $0.50 per share, an improvement from $0.49 a year earlier. These metrics indicate a positive growth momentum in both revenue and earnings, contributing to a favorable view of Bio-Techne's stock performance.
Bears say
Bio-Techne is facing significant headwinds due to the escalation of U.S. tariffs and proposed funding cuts of up to 40% for key agencies such as the NIH, which are expected to negatively impact revenues and gross margins in the fourth quarter of fiscal year 2025. The company has adjusted its financial estimates for the upcoming quarter, anticipating slower-than-expected revenue growth and margin contraction. These challenges could hinder Bio-Techne’s financial performance, particularly given that a substantial portion of its revenue relies on U.S. sales and government funding for life sciences research.
This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.
Bio-Techne (TECH) Analyst Forecast & Price Prediction
Start investing in Bio-Techne (TECH)
Order type
Buy in
Order amount
Est. shares
0 shares